Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
By Jeffrey S. Damrauer, Katherine A. Hoadley, D. Chism, C. Fan, Christopher J. Tiganelli, Sara E. Wobker, J. Yeh, M. Milowsky, G. Iyer, J. Parker and 1 more. Proceedings of the National Academy of Sciences of the United States of America, 2014
838 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a929810a2acddf8ba34334ad5a2608f1ab4a2c1c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Peter W. Laird
- S. Baylin
- Gad Getz
- Matthew Meyerson
- Yiling Lu
- Benilton S. Carvalho
- John N. Weinstein
- Inanç Birol
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity (2014, neutral): “b | Damrauer et al.(173) classified bladder cancer into basal and luminal subtypes.”
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. (2017, positive): “The analysis confirmed the two major luminal and basal transcriptional subtypes identified by TCGA and other groups (Choi et al., 2014b; Damrauer et al., 2014; Sjodahl et al., 2012), while discriminating within those subtypes and identifying luminal and neuronal subtypes (see below).”
- Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures (2019, methodology): “To explore the correlation between the TME signature and other relevant biological processes, we used gene sets curated by Mariathasan and colleagues (13), including (i) CD8 T-effector signature (11); (ii) antigen processingmachinery (37); (iii) immune-checkpoint; (iv) epithelial–mesenchymal transit”
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. (2016, background): “Interestingly, recent genomic data have described a basal/squamous-like molecular subtype that has squamoid morphology and immunophenotype and is associated with poor survival and poor response to systemic therapy [69,70].”
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017, neutral): “claudin-low, basal, and luminal subtypes [12,15].”
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2019, methodology): “We refer to these input classifications as Baylor (Tumour differentiation)13, UNC7, CIT-Curie8, MDA9, Lund10, and TCGA2.”